Update on the Therapeutic Management of Hepatic Encephalopathy

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Update on the Therapeutic Management of Hepatic Encephalopathy. / Kornerup, Linda Skibsted; Gluud, Lise Lotte; Vilstrup, Hendrik; Dam, Gitte.

I: Current Gastroenterology Reports, Bind 20, Nr. 5, 21, 2018.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Kornerup, LS, Gluud, LL, Vilstrup, H & Dam, G 2018, 'Update on the Therapeutic Management of Hepatic Encephalopathy', Current Gastroenterology Reports, bind 20, nr. 5, 21. https://doi.org/10.1007/s11894-018-0627-8

APA

Kornerup, L. S., Gluud, L. L., Vilstrup, H., & Dam, G. (2018). Update on the Therapeutic Management of Hepatic Encephalopathy. Current Gastroenterology Reports, 20(5), [21]. https://doi.org/10.1007/s11894-018-0627-8

Vancouver

Kornerup LS, Gluud LL, Vilstrup H, Dam G. Update on the Therapeutic Management of Hepatic Encephalopathy. Current Gastroenterology Reports. 2018;20(5). 21. https://doi.org/10.1007/s11894-018-0627-8

Author

Kornerup, Linda Skibsted ; Gluud, Lise Lotte ; Vilstrup, Hendrik ; Dam, Gitte. / Update on the Therapeutic Management of Hepatic Encephalopathy. I: Current Gastroenterology Reports. 2018 ; Bind 20, Nr. 5.

Bibtex

@article{9c9e3e034730497d8cf85735aae61c66,
title = "Update on the Therapeutic Management of Hepatic Encephalopathy",
abstract = "PURPOSE OF REVIEW: Hepatic encephalopathy (HE) is a common and devastating complication to chronic liver disease. In this paper, we summarize the latest research and evidence of both conventional and up-coming treatments.RECENT FINDINGS: Meta-analyses report beneficial effects of lactulose, branched-chain amino acids, rifaximin, and to some degree L-ornithine L-aspartate on the manifestations of HE in patients with cirrhosis, and generally the numbers needed to treat are low. Recent studies on newer HE treatments including ornithine phenylacetate, spherical carbon, and fecal microbiota transplant also report potentially beneficial effects on HE manifestations. The conventional treatments benefit patients with HE. Newer treatments are under study and more research is needed for their validation.",
keywords = "Amino Acids, Branched-Chain/therapeutic use, Anti-Bacterial Agents/therapeutic use, Disease Management, Fecal Microbiota Transplantation, Gastrointestinal Agents/therapeutic use, Hepatic Encephalopathy/drug therapy, Humans, Lactulose/therapeutic use, Probiotics/therapeutic use, Rifamycins/therapeutic use, Rifaximin",
author = "Kornerup, {Linda Skibsted} and Gluud, {Lise Lotte} and Hendrik Vilstrup and Gitte Dam",
year = "2018",
doi = "10.1007/s11894-018-0627-8",
language = "English",
volume = "20",
journal = "Current Gastroenterology Reports",
issn = "1534-312X",
publisher = "Current Medicine Group LLC",
number = "5",

}

RIS

TY - JOUR

T1 - Update on the Therapeutic Management of Hepatic Encephalopathy

AU - Kornerup, Linda Skibsted

AU - Gluud, Lise Lotte

AU - Vilstrup, Hendrik

AU - Dam, Gitte

PY - 2018

Y1 - 2018

N2 - PURPOSE OF REVIEW: Hepatic encephalopathy (HE) is a common and devastating complication to chronic liver disease. In this paper, we summarize the latest research and evidence of both conventional and up-coming treatments.RECENT FINDINGS: Meta-analyses report beneficial effects of lactulose, branched-chain amino acids, rifaximin, and to some degree L-ornithine L-aspartate on the manifestations of HE in patients with cirrhosis, and generally the numbers needed to treat are low. Recent studies on newer HE treatments including ornithine phenylacetate, spherical carbon, and fecal microbiota transplant also report potentially beneficial effects on HE manifestations. The conventional treatments benefit patients with HE. Newer treatments are under study and more research is needed for their validation.

AB - PURPOSE OF REVIEW: Hepatic encephalopathy (HE) is a common and devastating complication to chronic liver disease. In this paper, we summarize the latest research and evidence of both conventional and up-coming treatments.RECENT FINDINGS: Meta-analyses report beneficial effects of lactulose, branched-chain amino acids, rifaximin, and to some degree L-ornithine L-aspartate on the manifestations of HE in patients with cirrhosis, and generally the numbers needed to treat are low. Recent studies on newer HE treatments including ornithine phenylacetate, spherical carbon, and fecal microbiota transplant also report potentially beneficial effects on HE manifestations. The conventional treatments benefit patients with HE. Newer treatments are under study and more research is needed for their validation.

KW - Amino Acids, Branched-Chain/therapeutic use

KW - Anti-Bacterial Agents/therapeutic use

KW - Disease Management

KW - Fecal Microbiota Transplantation

KW - Gastrointestinal Agents/therapeutic use

KW - Hepatic Encephalopathy/drug therapy

KW - Humans

KW - Lactulose/therapeutic use

KW - Probiotics/therapeutic use

KW - Rifamycins/therapeutic use

KW - Rifaximin

U2 - 10.1007/s11894-018-0627-8

DO - 10.1007/s11894-018-0627-8

M3 - Review

C2 - 29644492

VL - 20

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1534-312X

IS - 5

M1 - 21

ER -

ID: 216513524